Health Canada Approves LEQEMBI for Early Alzheimer's Treatment
Eisai and Biogen Canada Inc. announced that Health Canada has authorized LEQEMBI (lecanemab) for treating early Alzheimer's disease.
LEQEMBI is indicated for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, specifically those who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.
Contact information: 877-269-7890 from 8 AM - 10 PM ET.
No direct quote available in the provided text.
Author's summary: Health Canada approves LEQEMBI for early Alzheimer's treatment.
More News
- Why Every Venue Needs Its Own ‘Black Box’ for Public Safety
- Importing beef is not the solution | GABEL
- Tonight’s ‘Sports Equinox’ will showcase games throughout the NFL, MLB, NBA and NHL
- Winners and losers from Argentina’s pivotal midterm election
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- SLO County Touts Improved Public Safety with Opening of New Communications Center | News Channel 3-12
- Hospital redevelopment: what the first year of construction will look like
- Battlefield 6 REDSEC battle royale to officially launch soon
- Man Utd Failed With £50 Million Mbeumo Alternative
- Acres.com to collaborate with UA System’s Fryar Center - Talk Business & Politics